A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has ...

US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Novo is in a strong financial position to continue its exploration focus on Western Australia and Victoria, with no debt and ...

On the Board of Page, Dr. Gaugler joins Prof. Nicola Aceto, scientific founder, Prof. Christoph Rochlitz, MD, co-founder and CMO, as well as Daniele Scarinci, President and CEO and Ciro Spedaliere, ...

“That’s the grand vision,” says Ms. Yu. The company has provided its bioplastic solution to Amazon, Novo Nordisk, and Sodexo, ...

The company was founded by Epidarex Capital. It has gone on to attract some big-name investors including Novo Ventures, and Sanofi Ventures. Cowen Healthcare Investments, F-Prime Capital ...

Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...

MALHAM, Saudi Arabia, Oct. 20, 2024 /PRNewswire/ -- Tahaluf, organizers of the Global Health Exhibition , today announced advance registrations for the event opening in Riyadh tomorrow have surpassed ...

Novo Nordisk's chief scientific officer Marcus ... often putting its faith in high-risk ventures. That was the thinking applied to the formation of Moderna, which paid off spectacularly with ...